Published
7 months agoon
By
adminJohnson and Johnson is a buy as executives project strong medicine sales over the next two years and as the company expands its drug-making operations in the U.S., according to Wells Fargo. The bank upgraded the pharma giant to overweight from equal weight. It also raised its price target for shares to $212 from $170, implying about 14% upside. “Given the potential upside to JNJ’s Pharma business, lower Pharma tariff and pricing risk, and investor confidence that JNJ can grow through the Stelara LOE, we could see JNJ’s valuation move higher,” analyst Larry Biegelsen said Friday in a note to clients. Several of the drugmaker’s cancer-related treatments, including Rybrevant, have seen higher demand in recent quarters and are poised to gain even more traction in the market, Wells Fargo said. Biegelsen also highlighted that Johnson & Johnson executives recently expressed confidence that their pharmaceutical sales will improve each year between 2025 and 2027, despite the Street’s estimates that demand for the firm’s drugs will deaccelerate during that time. “We believe JNJ’s recent track record bodes well for its ability to meet/exceed its target,” Biegelsen wrote, adding that Johnson & Johnson previously exceeded its $57 billion pharmaceutical revenue goal for 2025 a year ahead of schedule. More broadly, the company’s margins are likely to improve as tariff tailwinds from last April moderate, according to Wells Fargo. The drug company is also poised to become more resilient to future trade tailwinds as it pours massive amounts of funds into ramping up its pharmaceutical manufacturing stateside, the bank said. J & J unveiled plans to invest $55 billion in its research and drug manufacturing businesses in the U.S. over the next four years, in addition to pledging to pour $2 billion to expand its pharmaceutical manufacturing in North Carolina. Wells Fargo’s rating for Johnson & Johnson falls in line with the majority of the Street’s calls on the stock. Fourteen of the 27 analysts who cover the company have a buy or strong buy rating on shares, according to LSEG data. Johnson & Johnson shares ticked up roughly 1% in premarket trading on Friday. The stock has risen nearly 16% over the past year.
This industrial giant is emerging as a big AI play, says Wells Fargo
Novo Nordisk’s strategy tested as investors push back on board revamp
Alibaba plans AI subscriptions, stablecoin-like payments with JPMorgan
UK borrowing costs spike on report government to scrap plans to raise income tax
Trump’s threatened the BBC with a $1B lawsuit: Here’s what’s going on
UBS’s picks for global returns next year
Wells Fargo sees Caterpillar continuing to roar higher, emerging as an artificial intelligence play. The bank initiated shares of...
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic...
Key Points Alibaba plans to use “tokenization” of payments for cross-border transactions in its business-to-business arm. Kuo Zhang, president...
Rachel Reeves, U.K. chancellor of the exchequer, delivers a speech in London, UK, on Tuesday, Nov. 4, 2025. Bloomberg...
US President Donald Trump speaks to reporters as he arrives at Palm Beach International Airport on Oct. 31,...
Investors looking for global diversification opportunities should look to a specific subset of stocks in Europe, according to UBS...
Eakarat Buanoi | Istock | Getty Images LISBON, Portugal — Top tech executives told CNBC they’re concerned about...
Tan Su Shan, deputy chief executive officer and managing director of institutional banking at DBS Group Holdings Ltd., speaks during...
CHENGDU, CHINA – OCTOBER 18: People walk past the Louis Vuitton store at Taikoo Li, a high-end shopping area that...
The United States said Thursday it will remove tariffs on some foods and other imports from Argentina, Ecuador, Guatemala and...
